Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2018-09-20 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于部分理财产品到期赎回的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhuhai Jianfan Biotechnology Co., Ltd. regarding the progress of redemption of certain financial products. It details the company's use of idle funds for cash management, investment risks, risk mitigation measures, and the impact on the company. It also lists the main financial products purchased in the past twelve months and their status. The document references prior shareholder meeting resolutions and previous announcements but does not contain comprehensive financial statements or detailed financial performance data. The content is focused on updates about financing activities related to cash management and investment products, rather than a full financial report or earnings release. The document length is about 4706 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP), as it provides updates on the company's cash management and investment activities with idle funds.
2018-09-20 Chinese
第三届董事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Zhuhai Jianfan Biotechnology Co., Ltd. It details the convening of the third board's 22nd meeting, attendance, and the approval of a proposal to establish a Beijing branch. The document includes voting results and references compliance with company law and articles of association. There is no financial data, no mention of annual or quarterly reports, no audit information, and no investor presentation. The content is clearly about board decisions and management actions. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a substantive board resolution announcement. Confidence is high due to clear keywords like '董事会会议决议公告' (Board meeting resolution announcement) and detailed voting results on a management decision.
2018-09-10 Chinese
关于设立北京分公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhuhai Jianfan Biotechnology Co., Ltd. about the establishment of a new branch office in Beijing. It includes details about the branch's name, nature, address, business scope, and investment amount. The document mentions that the decision was approved by the company's board of directors and does not require shareholder approval. There is no financial data, no mention of annual or quarterly reports, no voting results, no executive changes, and no regulatory certifications. The content is about a corporate structural change (setting up a branch) rather than a financial report or regulatory filing. This fits best under the category of a general regulatory announcement about company operations, which aligns with Regulatory Filings (RNS). The document is short and does not contain financial statements or detailed management discussion, so it is not an Annual Report or Interim Report. It is not a Board/Management Information filing about personnel changes, but rather about a business operation decision. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-09-10 Chinese
关于使用部分闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the company's use of idle funds for cash management, detailing purchases and redemptions of financial products, investment risks, and measures taken. It references prior shareholder meeting resolutions and previous announcements but does not contain comprehensive financial statements or detailed financial performance data. The document is a regulatory announcement about financing activities and cash management updates rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is about 4972 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report.
2018-09-03 Chinese
关于部分高级管理人员减持股份的预披露公告
Transaction in Own Shares Classification · 95% confidence The document is a pre-disclosure announcement regarding the planned reduction of shares held by a senior management member (Vice General Manager Zeng Kai) of the company Zhuhai Jianfan Biotechnology Co., Ltd. It details the number of shares to be sold, the reasons, the method, and the timing of the sale. The document includes assurances about compliance with relevant laws and regulations and confirms that the reduction will not affect control or governance structure. This type of document is a report of a transaction in own shares by a company executive, specifically a planned share reduction by a senior management individual. It is not a full financial report, earnings release, or regulatory filing about financial results or governance changes. It is not a voting result or capital change announcement. Therefore, the correct classification is Transaction in Own Shares (POS). The document length is short (1719 characters), but it contains substantive information about the share reduction plan, not just an announcement of a report publication or a certification. Confidence is high due to clear content and context.
2018-08-31 Chinese
中航证券有限公司关于公司2018年上半年持续督导期间跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导期间跟踪报告" which translates to a "Continuous Supervision Period Tracking Report" by a sponsoring institution (中航证券有限公司) regarding a listed company (珠海健帆生物科技股份有限公司) for the first half of 2018. It details the sponsor's review and supervision activities, including information disclosure, governance, fundraising supervision, and compliance with commitments. It does not contain financial statements or detailed financial analysis but rather focuses on monitoring and compliance activities during the supervision period. This type of document is typical of a sponsor's tracking report during a continuous supervision period after an IPO or listing, which is not an annual or interim financial report, nor an earnings release or audit report. It is a regulatory compliance and monitoring report related to the sponsor's duties. Given the content and nature, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance reports that do not fit other specific categories.
2018-08-08 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.